Entrepreneurship in Biotechnology Columbia University Graduate School of Arts and Sciences BIOT 4180 Columbia University GSAS BIOT 4180.

Slides:

Advertisements

Similar presentations

What are CFD’s In finance, a contract for difference (CFD) is a contract between two parties, typically described as "buyer" and "seller", stipulating.

Advertisements

Risk Management P.V. Viswanath Class Notes for EDHEC course on Mergers and Acquisitions.

E VALUATING A P OTENTIAL A CQUISITION OF B IOGEN I DEC Anna Arnold, Samina Islam, Sean Landrette, Duc Nguyen November 30 th, 2007.

Presentation Title | 1Overview | 1 Proprietary and Confidential Deal Making in a Risk Adverse Environment – Strategies for Survival and Ultimate Success.

© 2012 Cooley LLP, Five Palo Alto Square, 3000 El Camino Real, Palo Alto, CA The content of this packet is an introduction to Cooley LLP’s capabilities.

FRANCHISING, LICENSING, & HARVESTING: CASHING IN YOUR BRAND

Accessing Resources for Growth from External Sources

Accessing Resources for Growth from External Sources

Chapters 1 and 2. Learn as much as possible about the target and then complete the following steps: 1. Select the universe of comparable firms 2. Locate.

ISM 158 Lecture 3 Charles Schwab Case. Fig 1.7 Strategic Alignment Model Ideally, all four quadrants align to create value.

Presentation by: Jeffrey S. McCormick General Partner of Saturn Partners LLC CEO of Alternative Technology Resources, Inc. Saturn Partners.

Aswath Damodaran1 An Introduction to Valuation Spring 2001 Aswath Damodaran.

Stock Or Cash -- A Financial Perspective All Stock Deal A Plans to Acquire T in a Stock-for- Stock Deal With T Receiving $84.30 for Each Share of Its Common.

Derivatives Markets The 600 Trillion Dollar Market.

Principles of option pricing Option A contract that gives the holder the right - not the obligation - to buy (call), or to sell (put) a specified amount.

Entrepreneurship in Biotechnology Columbia University Graduate School of Arts and Sciences BIOT 4180 Columbia University GSAS BIOT 4180.

Mergers & Acquisitions For Managed Service Providers Robert J. Scott Scott & Scott, LLP

Entrepreneurship in Biotechnology Columbia University Graduate School of Arts and Sciences BIOT 4180 Columbia University GSAS BIOT 4180.

INVESTMENT BANKING LESSON 5 LEVERAGED BUYOUTS (LBO’s): How IB is Used in Leveraged Buyouts Investment Banking (2 nd edition) Beijing Language and Culture.

ENTR 452 Chapter 14: Accessing Resources for Growth

Alternative Financing for Entrepreneurs How Israeli Companies Can Access Alternative US Capital Sources from Strategic Buyers By Bruce Kobritz CALITC.ORG.

Before You Invest. For the purpose of personal finance corporations are either private or public. Private corporations are owned by individuals, families,

AIM How can you invest smartly when stock prices are declining? DO NOW How does short selling work? SELLING SHORT AND DCA.

AOF Entrepreneurship Unit 3, Lesson 8 NavBuigating siness Growth Copyright © 2009–2012 National Academy Foundation. All rights reserved.

1 3 RD Annual TBI Monique Létourneau Executive Vice-President & CFO September 21, 2007.

PAYMENTS AND ROYALTY RATES February 2008 Christi Mitchell, IP Director, Highbury Ltd.

1 Value Assessment of Development-Stage Assets Pharmaceutical Products, Medical Devices, and Related Intellectual Property Frank S. Castellana, M.D., Eng.Sc.D.

Entrepreneurship in Biotechnology Columbia University Graduate School of Arts and Sciences BIOT 4180 Columbia University GSAS BIOT 4180.

Special Issues in M&A Transactions for Marketed Products John A. Hurvitz Covington & Burling Washington, DC (202)

Investment in Maa TV Presentation to Michael Lynton July 9 th, 2012.

©2008, Promega Corporation. All rights reserved. ©2007, Promega Corporation. All rights reserved. Global Financial Crisis -- Practical Implications for.

Summer 2009 URG MBA Program Chapters M & A – Mergers and Acquisitions Classic Mergers Triangular Mergers Subsidiary is formed specifically for.

The State of the Massachusetts Life Science Industry - The Year in Review - June 2, 2011 MALSI | MA Life Sciences Innovation Day.

Mergers and Acquisitions Activity, Rationale, and Negotiation 1RW Melicher.

SESSION 7: FINANCE TOPICS COVERED Participants will produce a formal business plan that will include a component of each of the following: Week 1: Introduction.

New Company Name 1 Merger Tagline. New Company Name 2 Key Points of the Merger Merger or an Acquisition If an acquisition, who is acquiring whom Degree.

What are Drug Royalties?  Rights on the sales of different prescriptions drugs.

Watch List Presentations April 17, 2008 David Light, Phil Rosen, Tim Tyson.

EQUITY MARKET FORCES AND THE POTENTIAL FOR MERGERS AND ACQUISITIONS IN THE JUNIOR MINING SECTOR RICHARD CHASE.

Consolidation in the Pharmaceutical Industry

GROUP EXECUTIVE COMMITTEE REVIEW: Divestiture of SPE’s Shareholdings in HBO Central Europe and HBO Latin America October 7, 2009.

Baker & McKenzie LLP is a member firm of Baker & McKenzie International, a Swiss Verein with member law firms around the world. In accordance with the.

GenCo Sam Rana 12/16/13.

HBO Divestiture Opportunity September 14, Confidential --p. 2 Executive Summary SPE is revisiting its global channels portfolio and seeking to.

GENERAL EXECUTIVE COMMITTEE REVIEW: HBO Divestiture Opportunity October 7, 2009.

Entrepreneurship in Biotechnology Columbia University Graduate School of Arts and Sciences BIOT 4180 Columbia University GSAS BIOT 4180.

 A market in which stocks are down  Those who buy and sell stocks.

GENERAL EXECUTIVE COMMITTEE REVIEW: HBO Divestiture Opportunity October 7, 2009.

Harvesting and Exiting the Venture Sell the Business Chapter 14

Finding the Win-Win Deal P.V. Viswanath Class Notes for FIN 648: Mergers and Acquisitions.

What is a Stock? The Stock Market. Objectives: What is a Stock?  Explain why there is risk involved in stock ownership.  Make decisions as a group on.

Finance Stuff Merger & Acquisition Process Joe Nau.

Bank Merger. Merger Objectives Acquiring banks' desire to increase its return –by expanding geographically. –by acquiring new technology. –by achieving.

Presentation by Dr. Andreas O. Tobler October 19, 2010 Tento projekt je spolufinancován Evropským sociálním fondem a státním rozpočtem České republiky.

Presentation by Dr. Andreas O. Tobler September 1, 2011 Tento projekt je spolufinancován Evropským sociálním fondem a státním rozpočtem České republiky.

Chapter 03 Currency and Eurocurrency Derivatives Copyright © 2011 by the McGraw-Hill Companies, Inc. All rights reserved. McGraw-Hill/Irwin.

Hybrid Methods Hybrid Methods – Mix of Asset Based & Income Based Method.

Potential red flags – Business environment

Joint Ventures and the Option to Expand and Acquire

HW No. 1. Due WED FEB 10 page 1 of 2 The table below describes options prices for a stock MMM on AUG The strike prices Are in the leftmost.

Effectual Strategy Peter Kelly

Technology Commercialization & Industry Partnering

Company Actuary Role in Mergers and Acquisitions

Costs, Revenue and Profit

Corporate Finance John Collins.

Presentation to Michael Lynton July 9th, 2012 DRAFT June 29th, 2012

Accessing Resources for Growth from External Sources

Mergers and acquisitions

Presentation transcript:

Entrepreneurship in Biotechnology Columbia University Graduate School of Arts and Sciences BIOT 4180 Columbia University GSAS BIOT 4180

Week 11 Partnering, Mergers and Acquisitions and Exits Columbia University GSAS BIOT 4180

Small Company Perspective Late clinical and regulatory experience Risk mitigation Orphan drug sales force: 15+ Blockbuster drug sales force: Cost of sales person: $300, ,000 Minimal overlap in skill sets between development, regulatory and sales Columbia University GSAS BIOT 4180

Large Company Perspective Cash flow Product(s) Pipeline Platform Leverage existing assets (sales force eg) Columbia University GSAS BIOT 4180

Good and Bad Deals Roche acquiring Genentech – Herceptin, Avastin, Lucentis Pfizer acquires Warner Lambert – Lipitor Pfizer acquires Esperion – Nothing for 1.3B Columbia University GSAS BIOT 4180

2003: Medivation inlicenses Dimebon Sep 2006: Dimebon meets 5/5 endpoints at 6 months Columbia University GSAS BIOT 4180

June 2007: Dimebon benefits last 12 months Columbia University GSAS BIOT 4180

July 2008: Dimebon data published in Lancet Sep 2008: Pfizer deal announced Columbia University GSAS BIOT 4180

Deal variables Upfront payment Milestone payments Royalties Costs and profits Manufacturing Geography Co-promotion Options Contingent variable rights / other indications Columbia University GSAS BIOT 4180

Dimebon licensing deal 225M upfront payment 500M on approval 60:40 costs and profit split Columbia University GSAS BIOT 4180

Mar 2010 Dimebon fails pivotal trial Columbia University GSAS BIOT 4180

Stock vs Cash Stock as currency: implicit admission that the stock is over-valued Cash: straight-forward DCF calculation w/o need to include a “stock price currency exchange”

Columbia University GSAS BIOT 4180

Negotiation Dealing from strength Multiple buyer dynamic Never have no options Walking away Most programs / companies are bought, not sold